[go: up one dir, main page]

MY138141A - Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments - Google Patents

Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments

Info

Publication number
MY138141A
MY138141A MYPI20032755A MYPI20032755A MY138141A MY 138141 A MY138141 A MY 138141A MY PI20032755 A MYPI20032755 A MY PI20032755A MY PI20032755 A MYPI20032755 A MY PI20032755A MY 138141 A MY138141 A MY 138141A
Authority
MY
Malaysia
Prior art keywords
medicaments
substituted
preparation
indolinone derivatives
salts
Prior art date
Application number
MYPI20032755A
Inventor
Gerald Jurgen Dr Roth
Armin Dr Heckel
Thorsten Dr Lehmann-Lintz
Jorg Dr Kley
Frank Dr Hilberg
Jacobus C A Van Dr Meel
Ulrike Dr Tontsch-Grunt
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/en
Priority claimed from DE10328533A external-priority patent/DE10328533A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY138141A publication Critical patent/MY138141A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

THE PRESENT INVENTION RELATES TO INDOLINONE DERIVATIVES, SUBSTITUTED IN THE 6-POSITION, OF THE FORMULA IN WHICH R1 TO R6 AND X ARE AS DEFINED IN CLAIM 1, TO THEIR TAUTOMERS, ENANTIOMERS, DIASTEREOMERS, TO THEIR MIXTURES AND TO THEIR SALTS, IN PARTICULAR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, WHICH HAVE USEFUL PHARMACOLOGICAL PROPERTIES, IN PARTICULAR IN INHIBITING ACTION ON VARIOUS RECEPTOR TYROSINE KINASES AND ON THE PROLIFERATION OF ENDOTHELIAL CELLS AND VARIOUS TUMOUR CELLS, TO MEDICAMENTS COMPRISING THESE COMPOUNDS, TO THEIR USE AND TO PROCESSES FOR THEIR PREPARATION.
MYPI20032755A 2002-07-23 2003-07-22 Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments MY138141A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (en) 2002-07-23 2002-07-23 Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10328533A DE10328533A1 (en) 2003-06-24 2003-06-24 New 6-amino-substituted indolinone derivatives, useful e.g. for treating tumours and angiogenesis, are inhibitors of receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
MY138141A true MY138141A (en) 2009-04-30

Family

ID=30771725

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20032755A MY138141A (en) 2002-07-23 2003-07-22 Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments

Country Status (25)

Country Link
EP (1) EP1523473B1 (en)
JP (1) JP4401291B2 (en)
KR (2) KR20120003025A (en)
CN (1) CN1318403C (en)
AR (1) AR041188A1 (en)
AU (2) AU2003254557B2 (en)
BR (1) BR0312799A (en)
CA (1) CA2493436C (en)
DK (1) DK1523473T3 (en)
EA (1) EA008623B1 (en)
EC (1) ECSP055567A (en)
ES (1) ES2409062T3 (en)
HK (1) HK1081554A1 (en)
HR (1) HRP20050069A2 (en)
IL (1) IL166404A0 (en)
MX (1) MXPA04012937A (en)
MY (1) MY138141A (en)
NO (1) NO20050937L (en)
PE (1) PE20040701A1 (en)
PL (2) PL374879A1 (en)
RS (1) RS20050047A (en)
SA (1) SA03240430B1 (en)
TW (1) TWI343375B (en)
UY (1) UY27903A1 (en)
WO (1) WO2004009547A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (en) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AS AGENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
BRPI0609899A2 (en) * 2005-04-28 2010-05-11 Boehringer Ingelheim International Gmbh compounds for the treatment of inflammatory diseases, their use, pharmaceutical formulations, drug combinations and intermediate products
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
MX2010007949A (en) * 2008-01-25 2010-08-04 Boehringer Ingelheim Int Process for the manufacture of a 6-fluoro-1,2-dihydro-2-oxo-3h-in dol-3-ylidene derivative.
JP2011510032A (en) * 2008-01-25 2011-03-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Salt forms of 6-fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene derivatives, processes for their preparation and pharmaceutical compositions containing them
EP2471787A1 (en) 2008-07-29 2012-07-04 Boehringer Ingelheim International GmbH New compounds
WO2014061752A1 (en) * 2012-10-17 2014-04-24 国立大学法人岡山大学 Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug
CN104936944B (en) * 2012-12-06 2017-09-12 山东亨利医药科技有限责任公司 It is used as the dihydroindole ketone derivate of tyrosine kinase inhibitor
CN105461609B (en) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 A kind of preparation method of Nintedanib
CN114213396B (en) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 Indole-2-ketone compound and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1115704T1 (en) * 1998-09-25 2003-12-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6559173B1 (en) * 2001-09-27 2003-05-06 Allergan, Inc. 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
CA2461812C (en) * 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
AU2003254557B2 (en) 2010-07-22
NO20050937L (en) 2005-02-21
KR20120003025A (en) 2012-01-09
AR041188A1 (en) 2005-05-04
CA2493436C (en) 2011-11-08
PE20040701A1 (en) 2004-11-30
TW200413314A (en) 2004-08-01
PL374879A1 (en) 2005-11-14
JP2005533841A (en) 2005-11-10
UY27903A1 (en) 2004-02-27
ES2409062T3 (en) 2013-06-24
BR0312799A (en) 2005-05-03
AU2003254557A1 (en) 2004-02-09
RS20050047A (en) 2007-09-21
ECSP055567A (en) 2005-04-18
SA03240430B1 (en) 2008-03-23
CN1318403C (en) 2007-05-30
DK1523473T3 (en) 2013-06-03
AU2010202845A1 (en) 2010-07-22
CN1668589A (en) 2005-09-14
PL397821A1 (en) 2012-03-12
EP1523473A1 (en) 2005-04-20
MXPA04012937A (en) 2005-05-16
HRP20050069A2 (en) 2005-12-31
EP1523473B1 (en) 2013-02-27
EA008623B1 (en) 2007-06-29
HK1081554A1 (en) 2006-05-19
CA2493436A1 (en) 2004-01-29
IL166404A0 (en) 2006-01-15
TWI343375B (en) 2011-06-11
KR20050052456A (en) 2005-06-02
EA200500148A1 (en) 2005-08-25
WO2004009547A1 (en) 2004-01-29
JP4401291B2 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
MY127956A (en) Substituted indolines which inhibit receptor tyrosine kinases
WO2004026829A3 (en) Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
MX2011012353A (en) N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2, 3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS.
UA83101C2 (en) 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists
RS20050042A (en) Novel inhibitors of kinases
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TW200519104A (en) Quinazoline derivatives
IS8377A (en) Arylindenopyridine and arylindenopyrimidine and their use as antagonists of the A2A adenosine receptor
RS20050363A (en) Chk-,pdk-and akt-inhibitory pyrimidines,their production an use as pharmaceutical agents
HK1065707A1 (en) 4--substituted nucleosides
MX2007011695A (en) Substituted oxindole derivatives, medicaments containing the latter and use thereof.
MA28279A1 (en) INDOLE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS, IN PARTICULAR IKK2 INHIBITORS
AU3864500A (en) Substituted aza-oxindole derivatives
MY138141A (en) Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments
TW200630374A (en) Thiazolyldihydroindazoles
NO20080418L (en) Pyrido [2,3-D] pyrimidiride derivatives, process for their preparation and therapeutic use of the same
WO2001027080A3 (en) 5-substituted indolinones and use thereof as kinase and cyclin/cdk complex inhibitors
ATE389655T1 (en) PYRIMIDINE DERIVATIVES
TR200102008T2 (en) Use of pyridine derivatives for prophylaxis and treatment of cerebral ischemia.
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
TW200640904A (en) Quinazoline derivatives
BRPI0416994A (en) Advanced indolinone-based protein kinase inhibitors
GB0308201D0 (en) Novel compounds